Irish workers can thank Pfizer's off-patent meds for saving their jobs

One hundred Pfizer ($PFE) jobs once tapped for chopping are now safe, and the company's off-patent meds, like Lipitor, are the saviors. Patent expirations drove the pharma giant to announce cuts at its Ringaskiddy, Ireland, facility in 2012. But now, an unpredicted increase in manufacturing volumes of off-patent drugs will forestall most of the layoffs. More

 

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.